The CT-2A-Luc cell line is derived from a sub-cutaneous, non-metastatic murine glioma (astrocytoma) and is stably transduced with a firefly luciferase-EGFP reporter. CT-2A-Luc cells are marked by high levels of complex gangliosides and low distribution of the anti-angiogenic ganglioside GM3, as well as deficiency in the tumor suppressor PTEN/TSC2, a characteristic present in up to 70% of human high-grade glioma cell lines (2,3). CT-2A tumors are wild-type for p53 and recapitulate several features of human high-grade glioma, including high mitotic index and cell density, nuclear polymorphism, hemorrhage, pseudopalisading necrosis, and microvascular proliferation (4,5). Source:The parental CT-2A cell line was generated from a malignant astrocytoma formed via implantation of the carcinogen 20-methylcholanthrene in the cerebrum of a C57BL/6J mouse (6). The tumor was maintained through serial intracranial transplants prior to cell line isolation. The CT-2A-Luc luciferase cell line was clonally derived from CT-2A cells transduced with a lentiviral vector harboring a firefly luciferase (Fluc)-IRES-GFP cassette under control of the CMV promoter; cells were subsequently sorted for EGFP expression (7).
Synonyms: CT-2A Luciferase, CT2A Luciferase
Application: This product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact [email protected].